Skip to Content
Global News Select

ADRs Finish Lower; RedHill Biopharma, Pandora Among Companies Actively Trading

   By Kimberly Chin 
 

International stocks trading in New York closed lower Tuesday. The S&P/BNY Mellon index of American depositary receipts fell 0.6% to 165.55. The European index slipped 0.3% to 144.38. The Asian index fell 0.9% to 226.12. The Latin American index decreased 0.6% to 201.15. And the emerging-markets index declined 1.3% to 376.25.

RedHill Biopharma Ltd. ADRs tumbled 32% after the company said a Covid-19 pneumonia study missed its primary objective. Efficacy data showed consistent trends in favor of the opaganib arm, but endpoints didn't achieve statistical significance, the company said.

ADRs of Pandora AS, which trade over the counter, jumped 6.6% on Tuesday after the Danish jeweler set new financial targets and increased its share-buyback program by 3 billion Danish kroner ($476.5 million) to DKK3.5 billion.

BP PLC's ADRs slipped 1.6% after the British company on Tuesday said Anja-Isabel Dotzenrath, the former CEO of RWE Renewables, would help lead its pivot away from fossil fuels and into low-carbon energy. She replaces longtime BP executive Dev Sanyal, who is leaving the company to take on a new role at a privately held refining company.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

(END) Dow Jones Newswires

September 14, 2021 18:57 ET (22:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.